Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.

Ítems similars

• HIV-1 recombinant gp160 vaccine given in accelerated dose schedules
  per: Gorse, G. J., et al.
  Publicat: (1994)
• Effect of a recombinant HIV gp160 vaccine on monokine production.
  per: Dooley, D P, et al.
  Publicat: (1991)
• Heparin enhances the furin cleavage of HIV‐1 gp160 peptides
  per: Pasquato, A., et al.
  Publicat: (2007)
• Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study
  per: Cosgrove, Catherine A., et al.
  Publicat: (2016)
• Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
  per: Kovacs, J A, et al.
  Publicat: (1993)